ArticleCell biochemistry and biophysics2026
RHBDD2 Confers Insensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Ferroptosis Through the Wnt3a/β-Catenin/FTH1 Axis.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As a pseudoprotease member of the rhomboid family, rhomboid domain containing 2 (RHBDD2) has been demonstrated to be associated with 5‑FU resistance. Our previous work found that RHBDD2 is also upregulated by cisplatin (DDP) treatment in esophageal squamous cell carcinoma (ESCC). However, the effect of RHBDD2 on DDP sensitivity and the underlying molecular mechanisms remain poorly understood. In this study, we demonstrate that RHBDD2 regulates the sensitivity of ESCC cells to DDP in vitro. In vivo, RHBDD2 knockdown significantly enhanced the antitumor effect of DDP in a subcutaneous xenograft model of ESCC. Enrichment analysis of RNA‑seq data from ESCC cells with RHBDD2 knockdown revealed that RHBDD2 is involved in regulating the biological process of ferroptosis. RHBDD2 inhibited ferroptosis by upregulating ferritin heavy chain 1 (FTH1), a major iron storage protein, and FTH1 knockdown reversed RHBDD2‑induced insensitivity of ESCC cells to DDP in vitro. Mechanistically, RHBDD2 promoted Wnt3a secretion, which in turn inhibited the phosphorylation and ubiquitination of β‑catenin, thereby enhancing β‑catenin nuclear localization and its transcriptional activity. Inhibition of β‑catenin‑mediated transcription by ICG‑001 reversed RHBDD2‑upregulated FTH1 expression and DDP insensitivity in vivo. Furthermore, we found that RHBDD2 mRNA is modified by N
Indexed as
Identifiers
42440245What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.